The information regarding this transaction is sourced from an SEC filing published on the SEC EDGAR platform on August 17, 2026. The specific form type is not disclosed in the available documentation. As of the current date, the transaction remains pending regulatory approval and has not yet closed.
Four financial institutions are advising on the arrangement and syndication of these incremental facilities. JPMorgan Chase Bank, N.A., Barclays Bank PLC, and BofA Securities, Inc. are all serving as joint lead arrangers and bookrunners for the incremental facilities, with all three carrying lead status in the transaction. Bank of America, N.A. is also providing commitment as a lender, specifically committing to provide 33.33% of the principal amount of the Term A Incremental Facility and 30.5% of the principal amount of the Term B Incremental Facility.
No legal advisors to either party have been identified or disclosed in the available documentation.
The transaction contemplates the creation of two distinct tranches of incremental facilities: a Term A Incremental Facility and a Term B Incremental Facility. The commitment percentages for Bank of America differ across these two facilities, with the bank providing a larger proportional commitment to the Term A tranche than to the Term B tranche. No additional structural details regarding interest rate margins, pricing tiers, financial covenants, or other loan-specific terms have been disclosed in the materials reviewed.
Several material details regarding this transaction remain undisclosed or unknown. The specific tenor or maturity date of either the Term A or Term B Incremental Facility is not provided. The interest rate structure, margins, and all pricing details are not disclosed. The expected closing date for the transaction has not been communicated. The full syndication breakdown and commitment amounts for JPMorgan, Barclays, and BofA Securities beyond their roles as bookrunners are not specified. Additionally, the rationale for the transaction, the use of proceeds, and any conditions precedent to funding beyond the regulatory approval status remain unknown.